REG - Haleon PLC - Transactions in Own Shares

HALEONAnnouncement

18/05/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260518:nRSR6036Ea&default-theme=true

RNS Number : 6036E  Haleon PLC  18 May 2026

 

Haleon plc: Aggregated information - transactions in own shares

 

18 May 2026: Haleon plc (the "Company" or "Haleon") today announces the
purchase of 8,316,688 ordinary shares of £0.01 each in the Company (the
"Shares") for cancellation under its share buyback programme announced on 12
March 2026.

 

                                                    London Stock Exchange  CBOE (UK)/BXE  CBOE (UK)/CXE  Aquis
 Date of purchase:                                  11 May 2026
 Number of Shares purchased:                        1,338,672              850,639        989,996        -
 Highest price paid per Share (p):                  333.1000               333.0000       333.0000       -
 Lowest price paid per Share (p):                   326.6000               326.6000       326.6000       -
 Volume weighted average price paid per Share (p):  328.7510               328.3012       328.5150       -
 Date of purchase:                                  12 May 2026
 Number of Shares purchased:                        136,968                73,601         88,439         -
 Highest price paid per Share (p):                  332.0000               330.9000       332.0000       -
 Lowest price paid per Share (p):                   325.4000               325.4000       325.4000       -
 Volume weighted average price paid per Share (p):  327.7318               327.9542       327.6454       -
 Date of purchase:                                  13 May 2026
 Number of Shares purchased:                        607,723                502,225        490,052        -
 Highest price paid per Share (p):                  331.7000               331.7000       331.7000       -
 Lowest price paid per Share (p):                   329.9000               329.9000       329.9000       -
 Volume weighted average price paid per Share (p):  330.9437               330.8733       330.9219       -
 Date of purchase:                                  14 May 2026
 Number of Shares purchased:                        487,742                353,903        407,856        -
 Highest price paid per Share (p):                  332.8000               332.8000       332.8000       -
 Lowest price paid per Share (p):                   329.4000               329.4000       329.4000       -
 Volume weighted average price paid per Share (p):  331.1191               331.1758       331.1625       -
 Date of purchase:                                  15 May 2026
 Number of Shares purchased:                        950,986                408,698        629,188        -
 Highest price paid per Share (p):                  332.3000               332.3000       332.3000       -
 Lowest price paid per Share (p):                   329.0000               329.0000       329.0000       -
 Volume weighted average price paid per Share (p):  330.7060               330.7844       330.7188       -

 

Following the settlement of the above, the Company's registered share capital
is 8,871,945,578 ordinary shares of £0.01 each, of which 12,130,560 are
held as treasury shares. Therefore, the number of ordinary shares with voting
rights is 8,859,815,018 and this figure may be used by shareholders to
determine if they are required to notify their interest, or a change to their
interest, in Haleon under the FCA's Disclosure Guidance and Transparency
Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it
applies in the UK (the Market Abuse Regulation), a full breakdown of the
individual trades is available at the link below:

 

http://www.rns-pdf.londonstockexchange.com/rns/6036E_1-2026-5-15.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/6036E_1-2026-5-15.pdf)

 

This announcement does not constitute, or form part of, an offer or any
solicitation of an offer for securities in any jurisdiction.

 

This announcement and individual trade breakdown will also be available on the
Company's website at: www.haleon.com/investors
(http://www.haleon.com/investors) .

 

 Enquiries

 Investors                                                                       Media

 Jo Russell                              +44 7787 392441                         Zoë Bird                             +44 7736 746167
 Rakesh Patel                            +44 7552 484646                         Victoria Durman                      +44 7894 505730
 Email: investor-relations@haleon.com (mailto:investor-relations@haleon.com)     Email: corporate.media@haleon.com (mailto:corporate.media@haleon.com)

 

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better
everyday health. Our people, our brands, our research, our investment and our
innovation are aimed at improving the everyday health of consumers. Our
product portfolio spans six major categories - Oral Health, Vitamins, Minerals
and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and
Therapeutic Skin Health and Other. Our superior brands - such as Advil,
Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and
Voltaren - are trusted by more than one billion consumers and are recommended
by health professionals around the world.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSBLGDURSBDGLU



            Copyright 2019 Regulatory News Service, all rights reserved